Navigation Links
Phase 2 Trial of LX4211 Demonstrates Significant and Rapid Improvements in Multiple Parameters in Type 2 Diabetic Patients
Date:1/20/2010

>Dr. Philip M. Brown, senior vice president of clinical development at Lexicon.  "Rapid improvement in multiple parameters of diabetes, meaningful weight loss, a favorable safety profile and the fact that LX4211-treated patients exhibited improvements in clinically-important metabolic and cardiovascular parameters within four weeks on a single agent is remarkable."

The recently completed study was a four-week, randomized, double-blind, placebo-controlled study in 36 patients with type 2 diabetes.  Patients were randomized to receive either placebo (n=12) or LX4211, 150 mg (n=12) or 300 mg (n=12), once daily for 28 days.  Patients were sequestered, provided a controlled diet and monitored closely throughout the study period.

There was a marked decrease in fasting plasma glucose throughout the treatment period in both dose groups, with reductions at week four of 53.4 mg/dl and 65.9 mg/dl in the 150 mg and 300 mg dose groups, respectively, as compared to 15.1 mg/dl for placebo.  These decreases in fasting plasma glucose relative to placebo were statistically significant for both LX4211 dose groups (p=0.001 and p<0.001, respectively).  Notably, a substantial percentage (42%) of patients in the 300 mg dose group achieved fasting plasma glucose levels of <105 mg/dl at week four of dosing as compared to placebo (p=0.037).

Importantly, after only four weeks of dosing, average percent hemoglobin A1c (HbA1c), a measure of blood glucose levels over time, was significantly reduced by 1.15 in the 150 mg dose group (p=0.036) and by 1.25 in the 300 mg dose group (p=0.017), as compared to 0.49 in the placebo group.  HbA1c levels were reduced to less than or equal to 7% for half the patients in both dose groups; baseline levels were 8.22%, 8.50% and 8.20% for the 150 mg, 300 mg, and placebo groups, respectively. Patients in both dose groups also exhibited significantly improved glucose tolerance in resp
'/>"/>

SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related medicine technology :

1. Circassia Extends its Clinical-Stage Portfolio With Phase II Trials of T-Cell Vaccines Against House Dust Mite and Cat Allergies
2. STELARA(TM) Shows Greater Efficacy Than Etanercept for Treatment of Moderate to Severe Plaque Psoriasis: Phase 3 Comparator Study Published in The New England Journal of Medicine
3. Bionovo Announces Publication of Positive Results From the Phase 1B Clinical Trial of Bezielle (BZL101) for Metastatic Breast Cancer
4. Start of Phase II Study for Intranasal, Seasonal Influenza Vaccine deltaFLU
5. Spherix Completes Enrollment in NEET, a Phase 3 Clinical Trial Evaluating an Oral Drug for Type 2 Diabetes
6. Raptor Pharmaceutical Corp. Announces Publication of Results from Phase 2a Trial of DR Cysteamine for Treatment of Cystinosis
7. Alimera Announces Positive Results From the Two Phase 3 FAME(TM) Trials of Iluvien(R) in Patients With Diabetic Macular Edema
8. Results From Phase II Trial in Critical Care Medicine Showed Eritoran Tetrasodium (E5564) To Be Well Tolerated in Patients with Severe Sepsis
9. Soligenix Announces Initiation of a Phase 1/2 Clinical Trial of SGX201 for the Prevention of Acute Radiation Enteritis
10. Intra-Cellular Therapies Announces the Results of a Phase I PET Study for ITI-007 for the Treatment of Schizophrenia and Other Psychiatric Disorders
11. BioSpecifics Technologies Corp. Announces Top-Line Phase 2b Results for XIAFLEX(TM) for Treatment of Peyronies Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/18/2013)... , May 18, 2013 The ... , Occupy Psychiatry , and ... health care, announces a social media campaign showcasing ... traditional psychiatric model, which focuses on pathology and ... coincides with the American Psychiatric Association,s (APA) rollout ...
(Date:5/17/2013)...  Lakeland Industries, Inc. (NASDAQ: LAKE ), ... healthcare and to first responders on the federal, state ... the fiscal 2013 fourth quarter and year ended January ... market close and will conduct a conference call on ... (Logo: http://photos.prnewswire.com/prnh/20120611/NY21959LOGO ) The call ...
(Date:5/17/2013)... May 17, 2013   Shareholder rights attorneys  at ... Pharmaceutical, Inc. (NASDAQGS: AVEO) securities has filed a complaint ... Massachusetts .  The complaint alleges that ... Exchange Act of 1934 (the "Exchange Act") between January ... (Logo: http://photos.prnewswire.com/prnh/20130103/MM36754LOGO ) ...
Breaking Medicine Technology:New Social Media Campaign Features Stories Of Individuals Who Rejected Psychiatric Diagnoses 2New Social Media Campaign Features Stories Of Individuals Who Rejected Psychiatric Diagnoses 3Lakeland Industries to Report Fiscal Fourth Quarter and Year End Financial Results and Conduct Conference Call 2Aveo Pharmaceuticals, Inc. Sued by Investor 2Aveo Pharmaceuticals, Inc. Sued by Investor 3
(Date:5/20/2013)... Angeles, CA (PRWEB) May 20, 2013 Idol ... get bigger, thicker, darker and fuller eyelashes in a matter ... now available for online purchase with an extra pack offer ... Customers can easily access this offer on the Idol lash ... and showed to increase the eyelash density up to 82% ...
(Date:5/20/2013)... US Drug Watchdog says, "After talking with ... are now calling the transvaginal mesh failure issues the ... and the damages are literally beyond comprehension. We are ... women. According to the New York Times, in 2010, ... implanted vaginally to treat urinary incontinence. That was 2010 ...
(Date:5/20/2013)... 20, 2013 On May 14th, premiere ... testimonial about how one of its patients originally came ... after being diagnosed with giant papillary conjunctivitis. “Giant papillary ... the eye, and for one of our patients in ... allergy,” says the Medical Director of the Atlanta Vision ...
(Date:5/20/2013)... The Mesothelioma Victims Center says, "We are ... diagnosed with mesothelioma get shortchanged when it comes to ... members turned to a local personal injury law firm, ... and experienced mesothelioma lawyers in the nation. We also ... never even bother to explore their legal options, because ...
(Date:5/20/2013)... CA (PRWEB) May 20, 2013 ... MessageSolution, an industry leader in enterprise-class information archiving, ... Enterprise eDiscovery Platform 7.0, the latest release in ... all facets of the legal discovery lifecycle. MessageSolution ... in Los Angeles CA. , As the first ...
Breaking Medicine News(10 mins):Health News:Idol Lash Eyelash Growth Enhancer Now Offered Extra Pack for Limited Time Only at HealthCareSupplementz.com 2Health News:US Drug Watchdog Now Urges Transvaginal Mesh Failure Victims With Erosion To Call Them For The Names And Contacts Of The Best Women Attorneys 2Health News:Atlanta LASIK Practice Publishes a Patient’s Testimonial About Allergy to Contact Lenses 2Health News:Mesothelioma Victims Center Urges US Navy Veterans Diagnosed With Mesothelioma To Call Them For The Names Of The Nation's Best Mesothelioma Lawyers-Better Compensation 2Health News:Mesothelioma Victims Center Urges US Navy Veterans Diagnosed With Mesothelioma To Call Them For The Names Of The Nation's Best Mesothelioma Lawyers-Better Compensation 3Health News:MessageSolution Releases Enterprise eDiscovery Platform 7.0 at LegalTech 2013 West Coast Expo 2Health News:MessageSolution Releases Enterprise eDiscovery Platform 7.0 at LegalTech 2013 West Coast Expo 3Health News:MessageSolution Releases Enterprise eDiscovery Platform 7.0 at LegalTech 2013 West Coast Expo 4
... Allscripts (Nasdaq: MDRX ),the leading provider ... use to improve healthcare, announced today that,it will ... months ended September,30, 2007 after the stock market ... Eastern Standard Time on the same day, Allscripts ...
... HILL, N.C., Oct. 23 As companies transform ... with the art of selling while maintaining a ... in facilitating the changeover,the manager/supervisor is one of ... In fact, call center leaders recommend reducing ...
... For Minimizing Commercial Exposure To Microbes, CHARLOTTE, ... provider of commercial hygiene products and services, today,announced ... at the ISSA/Interclean,trade show in Orlando from October ... number of germ reduction strategies that have been ...
... Answers.com(TM) (NASDAQ:,ANSW) today announced that it ... HealthiNation, a leading digital health media ... (See example at, http://www.answers.com/topic/cholesterol .) Answers.com ... such as business,health, travel, technology, science, ...
... LOUIS, Oct. 23 Cejka Search, a ... recently,announced that several of its leaders will ... conferences: The Medical Group,Management Association (MGMA) 2007 ... (ACPE) Fall Institute and the American College ...
... - TimeToTalk.org Provides Parents Timely Tips and Tools to Keep Youth ... ... have numerous methods,to trick their parents and keep their social behavior secret ... and social functions can help teens shield their drug or alcohol,use from ...
Cached Medicine News:Health News:Allscripts to Announce Third Quarter 2007 Results on November 8th 2Health News:Allscripts to Announce Third Quarter 2007 Results on November 8th 3Health News:Call Center Excellence: Managing Service-To-Sales Cultural Transformation 2Health News:Swisher Launches Germ-Free Zone at ISSA 2Health News:Answers.com Adds HealthiNation Video Content to Answer Engine(TM) 2Health News:Cejka Search Experts Present Latest Developments in Physician and Healthcare Employment at Leading Industry Conferences 2Health News:Cejka Search Experts Present Latest Developments in Physician and Healthcare Employment at Leading Industry Conferences 3Health News:Don't Be 'Tricked' By Your Teen This Month - It's Time To Talk With Teens About Drug and Alcohol Use 2Health News:Don't Be 'Tricked' By Your Teen This Month - It's Time To Talk With Teens About Drug and Alcohol Use 3Health News:Don't Be 'Tricked' By Your Teen This Month - It's Time To Talk With Teens About Drug and Alcohol Use 4
Duet Lumbar Allografts are comprised of a raised cancellous inner core providing biomechanical properties for rapid healing. Specially designed instruments facilitate the insertion of Duet Allografts...
Lumbar Allograft with Osteoactive advantage. Promotes bone formation and faster incorporation. Derived from the proven technology behind Grafton DBM. Maintains structural integrity and strength....
Seletz-Gelpi Laminectomy Retractor, self-retaining with arms bent at right angles....
Scoville-Haverfield Hemilaminectomy Retractor...
Medicine Products: